BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 8,333 new ordinary shares of £0.10 each in the Company.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy.

Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced that its stockholders approved at a special meeting the acquisition of Hanger by Patient Square Capital, a leading dedicated health care investment firm.

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

Apellis Pharmaceuticals, Inc. announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan, an investigational targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

Carestream Health announced that it has successfully completed its recapitalization process and emerged from Chapter 11.

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2022.

Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus, announced that it has reached its initial goal to raise at least $5M in a Series Seed round of financing.

Ardelyx, Inc. announced that on September 26, 2022, the compensation committee of the company’s board of directors granted four new non-executive employees options to purchase an aggregate of 56,250 shares of the company’s common stock, and an aggregate of 26,000 Restricted Stock Units.